Minimum information reporting in bio–nano experimental literature

M Faria; M Björnmalm; KJ Thurecht; SJ Kent; RG Parton; M Kavallaris; APR Johnston; JJ Gooding; SR Corrie; BJ Boyd; P Thordarson; AK Whittaker; MM Stevens; CA Prestidge; CJH Porter; WJ Parak; TP Davis; EJ Crampin; F Caruso

Journal article

Minimum information reporting in bio–nano experimental literature

M Faria, M Björnmalm, KJ Thurecht, SJ Kent, RG Parton, M Kavallaris, APR Johnston, JJ Gooding, SR Corrie, BJ Boyd, P Thordarson, AK Whittaker, MM Stevens, CA Prestidge, CJH Porter, WJ Parak, TP Davis, EJ Crampin, F Caruso

Nature Nanotechnology | NATURE PUBLISHING GROUP | Published : 2018

DOI: 10.1038/s41565-018-0246-4

Download PDF

Abstract

Studying the interactions between nanoengineered materials and biological systems plays a vital role in the development of biological applications of nanotechnology and the improvement of our fundamental understanding of the bio–nano interface. A significant barrier to progress in this multidisciplinary area is the variability of published literature with regards to characterizations performed and experimental details reported. Here, we suggest a ‘minimum information standard’ for experimental literature investigating bio–nano interactions. This standard consists of specific components to be reported, divided into three categories: material characterization, biological characterization and d..

View full abstract

University of Melbourne Researchers

Matt Faria Author

Stephen Kent Author

Frank Caruso Author

Related Projects (3)

ARC CENTRE OF EXCELLENCE IN CONVERGENT BIO–NANO SCIENCE AND TECHNOLOGY

The CoE in Convergent Bio-Nano Science &Technology comprises a multi-disciplinary team focused on research aiming to understand and control ..

ENGINEERING MATERIALS FOR ADVANCES IN NANOMEDICINE

Nanomedicine is one of the fastest growing areas in nanotechnology. This project will develop next-generation particle systems with engineer..

ADVANCING NANOMEDICINE THROUGH PARTICLE TECHNOLOGY

This proposal will support the development of advanced particle systems to improve the delivery of medicines in neurological diseases, HIV, ..

Grants

Awarded by Horizon 2020 Framework Programme

Funding Acknowledgements

This work was supported by the Australian Research Council (ARC) Centre of Excellence in Convergent Bio-Nano Science and Technology (Project Number CE140100036) and under the ARC Australian Laureate Fellowship scheme (F.C., FL120100030; T.P.D., FL140100052; J.J.G., FL150100060). M.B. acknowledges support from H2020/European Commission through a Marie Sklodowska-Curie Individual Fellowship under grant agreement no. 745676. F.C. acknowledges the award of a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (APP1135806). M.K. receives support from NHMRC Principal Research Fellowship (M.K.; APP1119152) and Cancer Council New South Wales Program Grant (PG16-01). M.K., T.P.D. and J.J.G. receive support from NHMRC Program Grant (APP1091261). A.P.R.J. receives support from the NHMRC Career Development Fellowship (APP1141551) and NHMRC Project Grants (APP1129672, APP1124161). R.G.P. receives support from NHMRC Senior Principal Research Fellowship (APP1058565) and NHMRC Program Grant (APP1037320). W.J.P. acknowledges funding from the Deutsche Forschungsgemeinschaft (project DFG PA 794/28-1) and a visiting professor fellowship from the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology. M.M.S. acknowledges support from the ERC Seventh Framework Programme Consolidator grant "Naturale CG" [616417], the i-sense EPSRC IRC in Early Warning Sensing Systems for Infectious Diseases (EP/K031953/1) and the EPSRC grant "Bio-functionalised nanomaterials for ultrasensitive biosensing" (EP/K020641/1). The authors thank A. E. Burke and C. Lynm for assistance with the preparation of Fig. 1. The development of these guidelines was led by the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology (https://www.cbns.org.au/).